Loading...
01/11 16:22
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call highlights strong financial performance with an 18% sales growth, expansion into new markets, and optimistic future revenue expectations. The Q&A session reveals positive growth in new and repeat customers and strategic market expansion, particularly in the AYA segment, despite some reluctance to share specific numbers. The company's strategy to enhance programs and expand in Europe and Japan indicates a proactive approach, supporting a positive sentiment. However, the lack of specific guidance and royalty impact tempers the outlook slightly, leading to a positive rather than strong positive rating.
Revenue Revenue grew 33% year-over-year and 10% sequentially with net revenues of $9.7 million. This growth reflects disciplined execution, an overhauled go-to-market strategy, and the addition of 14 new accounts, including large community oncology groups.
Net Product Sales Net product sales were $9.7 million, representing a 33% increase compared to the same period last year and 10% growth over the first quarter of this year. This growth is attributed to successful retention of existing customers and new uptake in demand for PEDMARK.
Cash Operating Expenses Total cash operating expenses for the quarter were approximately $11 million, an increase of roughly $2 million compared to the first quarter of this year. The increase was driven by ongoing investments in marketing, additional headcount, and intellectual property efforts.
Selling and Marketing Expenses Selling and marketing expenses were $4.4 million in the second quarter of 2025 compared to $2.9 million in the first quarter of 2025 and $4.7 million in the second quarter of 2024. The increase was primarily due to additional marketing expenses and a one-time accrual reversal in Q1 2025.
General and Administrative (G&A) Expenses G&A expenses were $7 million in the second quarter of 2025 compared to $6.1 million in the first quarter of 2025 and $6.9 million in the second quarter of 2024. The increase was largely due to increased noncash stock compensation and ongoing litigation and intellectual property expenses.
Cash and Cash Equivalents Cash and cash equivalents were approximately $18.7 million as of June 30, 2025. The company expects full-year cash operating expenses to be similar to 2024, roughly $33 million, with potential increases in cash balance from product revenues, milestones, and partnerships.
PEDMARK adoption: PEDMARK is the first and only FDA-approved therapy in the U.S. and Europe to reduce the risk of cisplatin-induced ototoxicity (CIO). It has been added to the formulary of a large national oncology group for patients under 40 years of age. NCODA issued a positive quality intervention (PQI) for PEDMARK, providing practical guidance for its use.
Revenue growth: Net revenues for Q2 2025 were $9.7 million, a 33% year-over-year increase and 10% sequential growth. This marks the third consecutive quarter of growth.
Market expansion in Europe: PEDMARK (marketed as PEDMARQSI) has launched in the United Kingdom and Germany through a partnership with Norgine, with positive traction reported.
Operational efficiencies: The company has revamped its go-to-market strategy, resulting in disciplined execution and scalability. Investments in marketing, headcount, and intellectual property have been made to support growth.
Cost management: Cash operating expenses for Q2 2025 were $11 million, with expectations for these expenses to decrease in the second half of 2025. The company aims for cash profitability as revenues grow and expenses decline.
Strategic focus on PEDMARK: Efforts are concentrated on establishing PEDMARK as the standard of care for CIO prevention through education, advocacy, and multidisciplinary engagement.
Leadership and team restructuring: New leadership team members have been brought in to drive strategy, marketing, and medical education, contributing to the company's progress.
Market Adoption Challenges: Despite progress, there is still a need to further cement PEDMARK as the standard of care for CIO prevention, which indicates potential challenges in achieving widespread adoption among healthcare providers.
Regulatory and Intellectual Property Risks: The company faces ongoing litigation and intellectual property expenses, which could impact financial stability and operational focus.
Financial Sustainability: The company reported $11 million in cash operating expenses for the quarter, exceeding its net product sales of $9.7 million, raising concerns about financial sustainability and profitability.
Dependence on Partnerships: The company’s financial outlook partially depends on milestones and royalties from its partnership with Norgine, as well as potential monetization or partnerships in Japan, which introduces dependency risks.
Operational Cost Management: Increased marketing and headcount expenses, along with higher G&A costs, could strain resources if revenue growth does not keep pace.
Economic and Market Uncertainties: The company’s growth projections are contingent on market conditions and the successful execution of its commercial strategies, which are subject to external economic factors.
Revenue Growth Expectations: The company anticipates the most significant quarterly growth in the second half of 2025, driven by foundational pillars and initiatives implemented to optimize PEDMARK's growth.
PEDMARK Expansion: Fennec expects additional accounts within large community oncology networks to activate and prescribe PEDMARK in Q3 2025, reflecting growing demand and scalability of the model.
European Market Expansion: The launch of PEDMARQSI by Norgine in the EU is underway in the United Kingdom and Germany, with updates on milestones and royalties expected in future quarters.
Japan Study Results: The company plans to release results from the Japan study in Q4 2025, which may lead to potential monetization or partnership opportunities.
Cash Operating Expenses: Cash operating expenses are expected to decrease in the second half of 2025, aligning with the company's aim towards cash profitability.
The selected topic was not discussed during the call.
The earnings call highlights strong financial performance with an 18% sales growth, expansion into new markets, and optimistic future revenue expectations. The Q&A session reveals positive growth in new and repeat customers and strategic market expansion, particularly in the AYA segment, despite some reluctance to share specific numbers. The company's strategy to enhance programs and expand in Europe and Japan indicates a proactive approach, supporting a positive sentiment. However, the lack of specific guidance and royalty impact tempers the outlook slightly, leading to a positive rather than strong positive rating.
The earnings call presents mixed signals. Financial performance shows growth, but cash burn and competitive pressures are concerns. The international launch and market expansion are positive, but regulatory and supply chain risks loom. The Q&A reveals some management opacity, particularly around breakeven figures. Without a share repurchase plan and given the lack of strong guidance, the sentiment leans neutral. The absence of market cap data limits the assessment of stock price sensitivity.
The earnings call reflects strong financial performance with 18% sales growth, reduced marketing expenses, and strategic market expansions. The Q&A session highlights positive engagement in new markets and adherence improvements. Despite cash flow risks and competitive pressures, optimistic guidance and international launches in Germany and the UK are positive indicators. The breakeven target is within reach, and the management's strategy appears sound. These factors suggest a positive stock price movement over the next two weeks.
The earnings call reveals several concerns: a significant EPS miss, competitive pressures, supply chain challenges, financial risks, and unclear guidance on market share and clinical trials. Despite positive developments like debt repayment and international expansion, these issues overshadow the optimism. The negative sentiment from analysts, due to management's vague responses, further contributes to a likely negative stock price movement.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
